Aug 2026· International Journal of Molecular Sciences· Vol 27· 0 citations· 24 references
Medicine
TL;DR
Assessment of the role of germline CHEK2 variants in the development of different cancer types confirmed that CHEK2 c.470T>C is the most common variant in the patient group, and the contribution of this variant to hereditary cancer risk in the Russian population is modest.
Abstract
While pathogenic germline CHEK2 variants are known to increase cancer risk, there is currently insufficient evidence regarding the precise risk of developing malignant neoplasms associated with specific missense variants or variants of uncertain significance. As a result, no clear clinical guidelines exist regarding consultation, monitoring and specific treatment options for those patients. For the first time in Russia, clinical data and whole-genome sequencing (WGS) results were analyzed for 3150 patients with cancer and suspected hereditary cancer syndromes (HCS) and 5163 healthy individuals. This dataset formed the basis for assessing the role of germline CHEK2 variants in the development of different cancer types. The chromosomal coordinates and coding sequence coordinates are given in accordance with the GRCh38 (hg38) genome assembly and the NM_007194.4 transcript. Pathogenic (P) and likely pathogenic (LP) variants of CHEK2 significantly increased the risk of breast cancer (OR = 2.015 [95% CI: 1.27–3.21]; p = 0.0031), but the association with colorectal cancer was not statistically significant (OR = 1.354 [95% CI: 0.42–4.42]; p = 0.616). A moderate increase in cancer risk was identified for the c.1100del variant (OR = 2.263 [95% CI: 1.19–4.32]; p = 0.0132) and for the common P/LP variants c.1100del, c.444+1G>A and c.433C>T (OR = 2.219 [95% CI: 1.40–3.51]; p = 0.0007). Notably, our study confirmed that CHEK2 c.470T>C (p.Ile157Thr) is the most common variant in the patient group, identified in 3.8% of cases (120/3150), compared with 3.0% in the control group (155/5163). Although the association between the most common CHEK2 variant c.470T>C and cancer risk reached nominal statistical significance (OR = 1.279 [95% CI: 1.00–1.63]; p = 0.0463), the effect size was minimal, suggesting that the contribution of this variant to hereditary cancer risk in the Russian population is modest. Additional studies are required before this variant can be definitively excluded from clinical interpretation.
Roles for certain genetic variants in CHEK2 in NB are supported, as well as potential mechanistic targets for high-risk or therapy-resistant NB, and preclinical information is provided to inform diagnostics and potential therapeutic strategies for high-risk NB.
Xue-Ting Xiong, Meagan Beffort, L. Kee et al.· Cancer Research· 0 citations
TP53
Y220C is a rare genomic alteration (GA) with emerging targeted therapies. However, its prevalence in breast cancer remains undefined. We evaluated the prevalence of the Y220C alteration and association with other GAs.
A total of 23,760 patients with advanced breast cancer were analyzed by hybrid ca...
N. Casasanta, Adriana M. Kahn, N. Fischbach et al.· JCO Oncology Advances· 0 citations
Pathogenic germline variants in BARD1 are strongly associated with neuroblastoma, and emerging evidence from our group and others suggests that heterozygous loss-of-function BARD1 variants may confer sensitivity to PARP inhibition, analogous to BRCA1-deficient cancers. This potential therapeutic vulnerability undersc...
Elizabeth M. Gonzalez, Rebecca S. Kaufman, Karina L. Conkrite et al.· Cancer Research· 0 citations
A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the priorit...
Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al.· Cancer Research· 0 citations
It is demonstrated that somatic rather than germline risk predominates in middle-aged healthy adults and the VAF-haplotype-sharing analysis framework provides a scalable framework for variant classification in large-scale population genomics.
H. A. MacGregor, J. Blundell, D. Easton· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.